Following Cathie Wood: significantly increased holdings in Block and Coinbase, reduced positions in SRTA and Robinhood

All three major U.S. stock indices closed lower on Wednesday: the S&P 500 ended at 7,420.10 points, down 1.21%; the Nasdaq Composite closed at 26,021.66 points, falling 1.34%; and the Dow Jones Industrial Average settled at 51,492.55 points, slipping 0.98%. The market is seeking a new equilibrium amid adjustments.

Faced with market volatility, Cathie Wood demonstrated her signature 'offense-and-defense-balanced' trading style—significantly increasing positions in blockchain and digital payment stocks while making structural adjustments to certain holdings, reflecting her long-term confidence in disruptive innovation sectors and precise allocation capabilities.

Buy-side focus: Emphasizing the underlying logic of digital payments and precision medicine

ARK's largest single-day purchase$Block (XYZ.US)$, buying 236,759 shares, reflecting strong confidence in the digital payments ecosystem. Block, the integrated fintech platform built by Jack Dorsey, is increasingly unlocking synergies between its Square ecosystem and Cash App, aligning with ARK’s investment theme of 'disintermediated financial infrastructure.'

Simultaneously significantly increased positions in$Coinbase (COIN.US)$111,799 shares, possibly signaling expectations of valuation repricing for crypto trading platforms amid clearer regulatory clarity. As the largest compliant cryptocurrency exchange in the U.S., Coinbase’s moat is becoming increasingly evident as institutional capital flows into the space.

In the field of healthcare innovation, ARK added$Eli Lilly and Co (LLY.US)$41,138 shares. The pharmaceutical giant’s breakthrough progress in GLP-1 weight-loss drugs and Alzheimer’s disease treatments aligns with ARK’s long-term positioning in the precision medicine revolution. ARK also made modest additions to$Generate Biomedicines (GENB.US)$9,617 shares and$Alamar Biosciences (ALMR.US)$8,148 shares, continuing to deepen exposure to cutting-edge AI-driven drug discovery and protein detection technologies.

Sell-side activity: Portfolio optimization and liquidity management

ARK significantly reduced its holdings$Strata Critical Medical (SRTA.US)$403,376 shares, reflecting a strategic adjustment in the medical devices sub-sector or considerations related to liquidity management and risk control.

It also reduced its position in$Robinhood (HOOD.US)$275,572 shares—a move that is particularly intriguing. Although Robinhood and Coinbase both fall under the fintech umbrella, ARK may believe that Coinbase holds stronger competitive advantages and greater growth potential in the digital asset infrastructure space, demonstrating a 'cut the weak, keep the strong' approach to portfolio allocation.

Additionally, it trimmed positions in$Roku Inc (ROKU.US)$239,267 shares,$Twist Bioscience (TWST.US)$80,140 shares, and$Baidu (BIDU.US)$912 shares, reflecting a phased cautious stance toward the competitive landscape of streaming platforms, the commercialization progress of synthetic biology, and the regulatory environment for Chinese ADRs.

Futubull’s [Opportunities Page] now features celebrity portfolio tracking! Choose from multiple celebrity holdings, follow top investors’ moves with one click, precisely target quality stocks, and invest with greater confidence!

160K Views